You are here

Viktor Adalsteinsson


Stover DG, Parsons HA, Ha G, et al. Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA. J Clin Oncol. 2017;35(15 suppl):1092.

Adalsteinsson VA, Ha G, Freeman SS, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8(1):1324.

Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32(5):479–484.

Zhang CZ, Adalsteinsson VA, Francis J, et al. Calibrating genomic and allelic coverage bias in single-cell sequencing. Nat Commun. 2015;6:6822.

Viktor Adalsteinsson, Ph.D.

Viktor Adalsteinsson is the associate director of the Gerstner Center for Cancer Diagnostics at the Broad Institute. He is also group leader for the Blood Biopsy Team in the Cancer Program at the Broad Institute of MIT and Harvard, a multi-institutional collaboration to profile cancer genomes directly from blood samples. The Blood Biopsy Team includes scientists, engineers, oncologists, and computational biologists spanning numerous investigators and labs at the Broad Institute, MIT, Dana-Farber Cancer Institute, Massachusetts General Hospital, and others. The goal of their research is to identify mechanisms of response and resistance to therapy, enable routine monitoring of patients with cancer, and eventually provide a mechanism for early detection of cancer.

Adalsteinsson joined the Broad Institute as a research affiliate during his doctoral studies at MIT and was subsequently tapped to lead the Blood Biopsy Team; he retains an affiliation with the Koch Institute for Integrative Cancer Research at MIT. Adalsteinsson holds a Ph.D. in chemical engineering from MIT (laboratory of J. Christopher Love), where he developed novel approaches for functional and genomic profiling of single cells in cancer. He has contributed to more than 14 publications and 5 patents with 500 citations in the fields of cancer biology, genomics, and biotechnology. Adalsteinsson was honored by MIT Technology Review in 2017 as a visionary member of its 35 Innovators Under 35.

Contact Viktor Adalsteinsson via email at

February 2019